Some results have suggested that As IV can reduce IL-4, IL-5, and IL-17 levels to inhibit asthmatic effects (Jin et al., 2017) and improve cardiac functions in children with viral myocarditis by reducing the levels of IL-17, IL-21, and caspase-3 (Zhang et al., 2018). This evidence concerns the gene IL5 and viral myocarditis.